| Literature DB >> 36132753 |
Cécile Naud1,2, Caroline Thébault1, Marie Carrière3, Yanxia Hou3, Robert Morel1, François Berger2, Bernard Diény1, Hélène Joisten1,4.
Abstract
Cancer treatment by magneto-mechanical effect of particles (TMMEP) is a growing field of research. The principle of this technique is to apply a mechanical force on cancer cells in order to destroy them thanks to magnetic particles vibrations. For this purpose, magnetic particles are injected in the tumor or exposed to cancer cells and a low-frequency alternating magnetic field is applied. This therapeutic approach is quite new and a wide range of treatment parameters are explored to date, as described in the literature. This review explains the principle of the technique, summarizes the parameters used by the different groups and reports the main in vitro and in vivo results. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 36132753 PMCID: PMC9419242 DOI: 10.1039/d0na00187b
Source DB: PubMed Journal: Nanoscale Adv ISSN: 2516-0230
Fig. 1Sketch of various types of magnetic particles exposed to variable magnetic fields, thus subjected to magneto-mechanical torques (and/or forces), tending to rotate (and/or translate) the particles. Average magnetic moment of the particle: black arrows; applied magnetic field B: red arrows; particle rotation or translation direction: blue arrows. (a) Effect of the magnetic torque, generated by a spatially uniform magnetic field (gradB = 0), tending to align the magnetic moment of the particle with the direction of the magnetic field B, leading to the particle rotation. = (B). A rotating magnetic field can thus cause stable rotation or vibration of the particle, synchronized on its frequency (provided the frequency is low enough). (b) Magnetic force produced by the magnetic field gradient – derived from a spatially non-uniform magnetic field (i.e. gradB ≠ 0) – leading to the particle translation towards regions of large magnetic fields. Variable magnetic field gradient may also produce particle vibration.
Fig. 2Representative scheme showing properties of particles with different shapes, associated sizes and materials, and obtained results: microscopy images of particles and magnetization curves (magnetization as a function of magnetic field). Extracted from: (a and b) Shen et al., 2017 (ref. 30) with (a) magnetization curve of dry particles at 300 K and (b) TEM images of iron oxide particles doped with zinc (l = 62 nm) [Reproducted with permission (ref. 30), Copyright© 2017, Ivyspring International Publisher, Theranostics]. (c) Kilinc et al., 2015:[34] SEM image of Fe–Au nanorods (d = 254 nm and l = 2 μm) [Reproducted with permission (ref. 34), Copyright© 2015, Wiley-VCH, Adv. Healthcare Mater.]. (d) Martínez et al., 2016:[35] SEM image of Fe nanowire (l = 6.4 ± 1.3 μm and d = 30–40 nm) [Reproducted with permission (ref. 35), Copyright© 2016, Springer Nature, Sci. Rep.]. (e) Contreras et al., 2015:[33] magnetization loops of an array of Ni nanowires (l = 4 μm and d = 30–40 nm) with magnetic field applied in the in-plane (black) and out-of-plane (red) directions [Reproducted with permission (ref. 33), Copyright© 2015, Dove Press, Int. J. Nanomed.]. (f and g) Wong et al., 2017 (ref. 36) with (f) hysteresis loop of NiFe particles with d = 150–350 nm (black to blue curve, respectively) and l = 500 nm, and (g) SEM images of NiFe particles of d = 350 nm and l = 75 nm, 200 nm and 500 nm (from left to right on the image) [Reproducted with permission (ref. 36), Copyright© 2017, Springer Nature, Sci. Rep.]. (h) Leulmi et al., 2015:[38] SEM image of NiFe particles (d = 1.3 μm and l = 60 nm) [Reproducted with permission (ref. 38), Copyright© 2015, Royal Society of Chemistry, Nanoscale]. (i) Mansell et al., 2017:[27] out-of-plane (red) and in-plane (black) hysteresis loops (b) for an array of 2 μm CoFeB/Pt particles and (d) for an array of 2 μm NiFe vortex particles [Reproducted with permission (ref. 27), Copyright© 2017, Springer Nature, Sci. Rep.]. (j) D. Cheng et al., 2014:[32] TEM image of iron oxide particles (d = 200 ± 50 nm) [Reproducted with permission (ref. 32), Copyright© 2014, Springer, Nanoscale Res. Lett.]. (k) Wo et al., 2016:[45] magnetization curve of hollow magnetic nanospheres of Fe3O4 (d = 250–550 nm) [Reproducted with permission (ref. 45), Copyright© 2016, Ivyspring International Publisher, Theranostics]. (l and m) Chiriac et al., 2018 (ref. 52) with (l) SEM image and (m) magnetization curve of Fe68.2Cr11.5Nb0.3B20 particles (l = 10–200 nm) [Reproducted with permission (ref. 52), Copyright© 2018, Springer Nature, Sci. Rep.].
Summary of particles properties, potential functionalization, and magnetic field sources, magnetic field amplitude, frequency and duration, and cancer cells properties, used in the literature for a TMMEP. Magnetic fields units (kA m−1; Oe; G) reported as used in references and converted in SI unit (T or mT)a,b,c
| Shape | References | Diameter | Length or thick-ness | Material | Functionalization | Chemo | Device | Field | Amplitude | Frequency | Duration | Cell line | Type1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cube | Shen | — | 62 nm | Zn–IO2 | DA–PAA–PEG + EGF peptide | — | Magnetic stirrer | Rotating | 40 mT | 15 Hz | 30 min × 3 days | U87 | Glioblastoma |
| Chen | — | 20 nm | Zn–IO2 | TPP3 | — | Magnetic stirrer | Rotating | 40 mT | 15 Hz | 30 min | U87 | Glioblastoma | |
| Nanowire | Fung | 200 nm | 4.4 μm | Ni | — | — | Magnetic stirrer | Rotating | 240 mT | 1 Hz | 20 min | NIH/3T3 | Fibroblast |
| Liu | 100 nm | 1 μm | C+4 | — | — | Magnetic stirrer | Rotating | 40–75 mT | 16.7 Hz | 20 min | MCF-7 | Breast cancer | |
| Wang | 80 nm | 580 nm | Fe | Silica | — | Oscillating magnet | Oscillat. or Grad. | 160 kA m−1 ∼ 200 mT | 2–10 Hz | 20–60 min | HepG2 | Hepatocellular carcinoma | |
| D. Cheng | 250–120 nm | 200 nm | Fe3O4 | — | — | Electro-magnet | Alternat. | 35 kHz | 0–10–30–60–120 min | HeLa5 | Metastases | ||
| Contreras | 35 nm | 4 μm | Ni | — | — | Coil | Alternat. | 0.5 mT | 1–1000 Hz | 10–30 min | HCT116 | Colorectal carcinoma | |
| Kilinc | 254 nm | 1.98 μm | Fe–Au | PEG + HRG | Yes6 | Electro-magnet | Alternat. + Grad. | — | 0.5 Hz (1 s ON + 1 s OFF) | 15 min | MCF7, MDA-MB-231 | Breast cancer | |
| Martínez | 30–40 nm | 6.4 μm | Fe | BSA, APTES | Yes7 | Electro-magnet | Alternat. | 1 mT | 10 Hz | 10 min | MDA-MB-231 | Breast cancer | |
| Cylinder | Wong | 150–350 nm | 50–500 nm | NiFe | — | — | 4 coils | DC, AC uni- or bi-axial pulsed | 140 Oe = 14 mT | 1–20 Hz | 10 min | HeLa4 | Metastases |
| Disk | Kim | 1 μm | 70 nm | Au/NiFe/Au | Anti-human-IL13a2R | — | Electro-magnet | Alternat. | 90 Oe = 9 mT | 10–60 Hz | 10 min | N10 | Glioma |
| Y. Cheng | 2 μm | 70 nm | Au/NiFe/Au | — | — | Halbach cylinder | Rotating | 1 T | 20 Hz | 5–30 min | U87 | Glioblastoma § | |
| Leulmi | 1.3 μm | 80 nm | Au/NiFe/Au | Anti-hCA9 | — | Magnetic stirrer | Rotating | 30 mT | 20 Hz | 45 min | SKRC59 hCA9 | Renal carcinoma | |
| Muroski | 2 μm | 60 nm | SAF8 | — | — | Halbach cylinder | Rotating | 1 T | 20 Hz | 30 min × 3 days | HB1.F3.CD, U87 | Neural stem cell, glioblastoma | |
| Zamay | 500 nm | 60 nm | Au/Ni/Au | AS-9 et AS-14 | — | Coil | Alternat. | 100 Oe = 10 mT | 100 Hz | 10 min | EAC | Elrich cell9 § | |
| Mansell | 2 μm | 118 nm, 70 nm | SAF7 or Au/NiFe/Au | — | — | Halbach cylinder | Rotating | 1 T | 20 Hz | 1 min | U87 | Glioblastoma | |
| Sphere | Hu and Gao 2010 ( | 180 nm + 15 nm | — | Janus nano-composite + Fe3O4 | PS16- | — | Magnetic stirrer | Rotating | — | 0.83 Hz | 15 min | LNCaP | Prostate tumor |
| Cho | 15 nm | — | Zn–IO | Ab for DR4 | — | 2 magnets | Grad. | 0.2 T | — | 2 h | DLD-1 | Colon cancer § | |
| Domenech | 61 ± 29 nm | — | Fe3O4 | CMDx + EGF | — | Coil | Alternat. | 42 kA m−1 ∼ 52 mT | 233 kHz | 1 h | MDA-MB-23, 184-B5 | Breast cancer, healthy mammary gland | |
| Wang | 0.2–2 μm | Fe | APTES | — | Oscillating magnet | Oscillat. Or Grad. | 160 kA m−1 ∼ 200 mT | 2–10 Hz | 20–60 min | HepG2 | Hepatocellular carcinoma | ||
| D. Cheng | 200 nm | — | Fe3O4 | — | — | Electro-magnet | Alternat. | 35 kHz | 0–10–30–60–120 min | HeLa4 | Metastasis | ||
| E. Zhang | 0.1–5.8 μm | — | Fe3O4 | Lamp-1 | — | Coils | Alternat.+ Grad. | 30 mT | 5–20 Hz | 20 min | INS1 | Rat insulinome | |
| Master | 7–8 nm | — | Fe3O4 | PAA(PMA)–PEG ou PAA-P85 | — | Electro-magnet | Alternat. Sinus. | 50 or 100 kA m−1 ∼ 62 or 125 mT | 50 Hz | 30 min or 3 × (10 min ON + 5 min OFF) | MDA-MB-231, BT474, MCF10A | Breast cancer, ductal carcinoma, healthy mammary gland | |
| Wo | 250–550 nm | — | Fe3O4 | SiO2/GQD + LB10 | Yes6 | 4 moving magnets | Alternat. | 45 mT | 2000 rpm | 20–60 min | Eca-109 | Esophageal cancer cells | |
| Ju | 40 nm | — | Fe3O4 | — | — | Coil | Alternat. | 0.7 mT | 100 Hz | HepG2, Bel-7402, HL-7702 | Hepatocellular carcinoma11, healthy hepatic cell | ||
| Brossel | 100 nm | — | Fe | — | — | 2 magnets | Gradient | 0.66 T | — | 2 h × 21 days | MDA-MB-231 | Breast cancer § | |
| Hapuarachchige | 80 nm | — | Fe3O4 | Starch | — | MRI | Alternat. Grad. in bias high field | 9.4 T | 5.4 kHz | 60 min | MDA-MB-231 | Breast cancer | |
| Vegerhof | 50–100–200 nm | — | Fe3O4 | PEG + C225 | Yes12 | Electro-magnet | Alternat.+ Grad. | 6.2 G = 0.62 mT | 4 Hz | 15 min | A431 | Skin cancer § | |
| Li | 30 nm | — | Fe3O4 | DMSA | — | 2 rotating magnets | Alternat. | 0.1–20 mT | 2–20 Hz | 1 h | MCF-7 | Breast cancer § | |
| Lunov | ∼60 nm | — | Fe3O4 | Carboxy-dextran | Coil | High field pulses of 15 μs | 5.5–8.5 T | ∼1.6 mHz | 100 s | Huh7, Alexander, HepG2 | Hepatocellular carcinoma, liver hepatoma, hepatoblastoma | ||
| Anisotropic | Chiriac | — | 10–200 nm | Fe–Cr–Nb–B | — | — | 4 coils | Rotating or Grad. | 1–20 Oe = 0.1–2 mT | 20–0–70–100 Hz | 5–10–15–20 min | HOS, NHDF | Osteosarcoma, healthy skin cell |
The § symbol is used to indicate in vivo studies; abbreviations: EGF: epidermal growth factor; Oscillat. = Oscillating; Grad. = Gradient; Alternat. = Alternating; Sinus. = Sinusoidal.
In the last column (“Type”) of the present Table 1, refers to “Apoptosis” mentioned as main cell death pathway, post-TMMEP, reported from the column 6 of Table 2.
1 Human cells, except mentioned. 2 Zn–IO: iron oxide doped with zinc. 3 Triphenyl-phosphonium cation. 4 5% metallic impurities. 5 Cervical cancer metastasis. 6 Vemurafenib. 7 Doxorubicin. 8 Synthetic antiferromagnet (SAF) composed of: Au/(Ta/Pt/CoFeB/Pt/Ru/Pt/CoFeB/Pt)/Au. 9 Mouse Ehlrich ascite adenocarcinoma. 10 Silica shell + graphene quantum dots + lipid bilayer. 11 Contamination by HeLa cells was recently demonstrated.[103]12 Cetuximab.
Percentage of cancer cells viability after full treatment (particles + field), compared with particle incubation and no field applied (particles) or in untreated cells (control). For clarity reasons, the results have been extrapolated and are expressed here as a percentage of viability, except for the results in italics. In this case, the LDH release is normalized to 1 for healthy cells, and expressed as a function of this value for the other conditions. In the absence of positive control, it is not possible to calculate a percentage of viability. The symbol † is used to indicate trypan blue cell counts with a haemocytometer (with the reserve that particles may be counted as dead cells). The authors refer to Table 1 where the exposure conditions are detaileda,b,c
| References | Experiment conditions | Test 1 | Test 2 | Test 3 | Main effects | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Particles + field | Particles | Control | Particles + field | Particles | Control | Particles + field | Parti-cles | Control | ||||||
| Fung |
| 11% | 100% | CK /— | ||||||||||
| Kim |
| ∼10% | ∼90% | CM /A | ||||||||||
| Hu and Gao, 2010 ( |
| 23% | 99% | 100% | CM /A | |||||||||
| Liu | 75 mT |
| 70% | 92% | 100% |
| ∼80% | ∼98% |
|
|
|
| CM & CL /— | |
| 40 mT |
| 83% | 92% | 100% |
| ∼83% | ∼98% |
|
|
|
| |||
| Cho |
| ∼48% | ∼95% | CM /A | ||||||||||
| Wang | Nanowire |
| 65–70% | ∼95% | CM /Nr | |||||||||
| Sphere |
| ∼70% | >95% | |||||||||||
| Domenech | NP + EGF |
| ∼70% | 100% |
| LP /A | ||||||||
| NP |
| ∼120% | 100% | |||||||||||
| NP + EGF |
| ∼100% | 100% |
| ||||||||||
| NP |
| ∼100% | 100% | |||||||||||
| E. Zhang | NP function. |
| 98% | 100% | LP /A | |||||||||
| NP |
| 99% | 100% | |||||||||||
| D. Cheng | Rod 1 h |
| ∼76% | ∼93% |
| ∼70% | 100% | CM /A | ||||||
| Rod 2 h |
| ∼60% |
| ∼70% | ||||||||||
| Sphere 1 h |
| ∼89% | ∼95% |
| ∼92% | 100% | ||||||||
| Sphere 2 h |
| ∼85% |
| ∼88% | ||||||||||
| Contreras | 1 kHz, 30 min |
| ∼62% | 100% |
| ∼66% | ∼88% | CM /Nr | ||||||
| 1 Hz, 30 min |
| ∼67% |
| ∼66% | ∼88% | |||||||||
| Master | Breast cancer |
| ∼50% | ∼95% | CK /— | |||||||||
| Breast cancer |
| ∼25% | ∼85–95% | |||||||||||
| Healthy cells |
| ∼82% | ∼95% | |||||||||||
| Y. Cheng |
| 40% | 80% | 100% |
| ∼10% | CM /A | |||||||
| Kilinc | 0.5 Hz |
| ∼50% | ∼97% | CM /— | |||||||||
| Leulmi |
| ∼20% | — | 100% | CM /A | |||||||||
| Wo | 20 min |
| ∼74% | 100–105% | CM /— | |||||||||
| 60 min |
| ∼58% | 100–105% | |||||||||||
| Muroski | NSC |
| 25% | 58% | CM /A, /CD | |||||||||
| Glioblastoma |
| ∼37% | 100% | |||||||||||
| Martínez-Banderas | NP + doxo. |
| ∼27% | ∼37% | ∼100% | IC /— | ||||||||
| NP |
| ∼65% | ∼95% | ∼100% | ||||||||||
| Hapuarachchige |
| ∼73% | ∼95–97% | IC /—, CD | ||||||||||
| Vegerhof |
| ∼49% | — | 100% | CM /Nr | |||||||||
| Wong | 1–5 Hz |
| ∼50% | — | ∼87% |
| ∼73% | 100% |
| ∼60% | ∼92% | CM /A | ||
| Li | 20 Hz 20 mT |
| ∼75% | >95% | CM /A | |||||||||
| Mansell | Vortex, 1 min |
| ∼88% | ∼99% | CM, IC /A, Nr | |||||||||
| SAF, 1 min |
| ∼38% | ∼99% | |||||||||||
| Shen | Day 1 |
| ∼65% | ∼130% |
| ∼43% | ∼98% | ∼98% | CM, LP /A, Nr | |||||
| Day 2 |
| ∼40% | ∼80% | |||||||||||
| Day 3 |
| ∼10% | ∼50% | |||||||||||
| Chen |
| ∼30% | ∼80% | ∼100% | CM, LP, IC /A | |||||||||
| Zamay | With AS-9 and AS-14 |
| ∼10% | ∼70% |
| CM /A | ||||||||
| Without |
| ∼35% | ∼70% | |||||||||||
| With AS-9 and AS-14 |
| ∼70% | ∼80% |
| ||||||||||
| Without |
| ∼60% | ∼80% | |||||||||||
| Chiriac | 20 Hz, 20 min |
| ∼55% | ∼95% | CM, LP, IC /A | |||||||||
| Lunov | 8 T 15 μs pulses |
| ∼40% | ∼105% | ∼95% | LP /A | ||||||||
| Ju | Drug delivery + NPs 100 Hz | — | CM /A | |||||||||||
Abbreviations: TB: trypan blue; CCK8 = WST-8 assay; Resaz.: resazurin assay, Lucif.: luciferase assay. NP: nanoparticle. EGF: epidermal growth factor.
Mainly mentioned effects of TMMEP on cells: CM: cellular membrane perturbation, (through membrane-bound or internalized particles); LP: lysosome perturbation (including on lysosomal membrane); CK: cytoskeleton and cytoplasm perturbation; CL: cell lysis; IC: intracellular perturbation.
Potentially initiating cell death pathways, in particular: /A: apoptosis; /Nr: necrosis or membrane rupture (leakage); /—: cell death, undefined pathway; CD: cell detachment.
Fig. 3Simplified diagrams of the mainly used magnetic field application devices. (a) Magnetic stirrer composed of two magnets at the end of a rotating rod (top view). (b) A coil powered by an alternating current that creates an alternating magnetic field inside or above the coil. The arrows in loops represent the magnetic flux line. (c) Ferrite core surrounded by a copper coil through which a sinusoidal alternating current flows. (d) System composed of 4 coils powered by an alternating sinusoidal current. The amplitude, phase shift and frequency of the applied current can be chosen to create an alternating or rotating field in the center of the 4 coils. (e) Halbach cylinder composed in this example of 8 permanent magnets creating an homogeneous field in the hollow of the cylinder. The rotating field is obtained by rotating the cylinder. (f) System composed of two magnets allowing to create a relatively homogeneous constant field.
Fig. 4(a) and (b) Extracted from Chiriac et al., 2018:[52] human osteosarcoma cells (a) before and (b) after the magneto-mechanical actuation (rotating field). Live cells are colored in green and dead cells in red [Reproducted with permission (ref. 52), Copyright© 2018, Springer Nature, Sci. Rep.]; (c–f) extracted from Hu and Gao, 2010:[41] prostate cancer cells after treatment: (c) cells only, (d) cells exposed to magnetic field, (e) cells with particles, (f) cells with particles and exposed to magnetic field. Particles are biphasic iron oxide nanocomposites (d = 180 nm). Rotating magnetic field (0.83 Hz) was applied for 15 min. Dead cells appear blue due to trypan blue staining [Reproducted with permission (ref. 41), Copyright© 2010, American Chemical Society, J. Am. Chem. Soc.]; (g and h) extracted from Liu et al., 2012:[31] cell membrane topographical imaging by AFM. (g) Control group. Surface of untreated cell was smooth. (h) MCF-7 cell treated by multiwalled carbon nanotubes exposed in 40 mT magnetic field for 20 min. Surface of the treated group is much rougher than controls with many small pore like structures [Reproducted with permission (ref. 31), Copyright© 2012, American Chemical Society, Nano Lett.].
Summary of in vivo studies of the effectiveness of TMMEP. The “Model” column indicates the model chosen as well as the type and number of cells used for tumor induction. The “Particle injection” column first indicates the time of injection of the particles, defined as a day (Day 0 corresponding to tumor induction) or depending on the diameter D of the tumor; then indicates the quantity of particles injected as well as the injection procedure. The “Molecules” column indicates the complementary molecules used. The “Magnetic field” column indicates the first time of exposure, defined as a specific day or depending on the volume V of the tumor or a delay after NP injection. The duration of exposure to the field and possible repetitions are then indicated. The “Study” column indicates the time of sampling, often defined as a duration after magnetic field exposure (MFE) as well as the methods used to evaluate the effectiveness of the TMMEP. The abbreviation HE stands for hematoxylin–eosin labelling
| Ref. | Model | Particle injection | Molecule | Magnetic field | Analysis | |||
|---|---|---|---|---|---|---|---|---|
| Timing | Procedure | Beginning | Duration | Timing | Procedure | |||
| Cho | Zebrafish | Day 0 | 2.5 ng injected in the vitellus | 24 h after NP | 24 h | Immediately after MFE | Tail angle, apoptosis | |
| Y. Cheng | Athymic nude mice 1 × 105 U87 cells in orthotopic model (brain) | Day 0 | 50 NP/cell injected with cells | From day 4 | 1 h × 7 days | Along study | Survival study, tumor volume monitoring | |
| Day 3 | 5 × 106 NP injected intra-tumoraly | From day 4 | 1 h × 7 days | Immediately after MFE | Apoptosis observation, HE label | |||
| Zamay | ICR white mouse 1 × 106 EAC cells in the leg | Day 7 | 2 × 107 NP/100 μl PBS injected intra-tumoraly | AS-9 and AS-14 | 1 h after NP | 10 min | 4 h after MFE | HE label |
| Vegerhof | Nude mice 2 × 106 A431 cells subcutaneous |
| 6 mg of NP in 200 μl injected intravenously | Cetuximab | 2 h after NP | 30 min × 7 in 14 days | Week 3 | Tumor volume monitoring |
| Brossel | BALB/C mice 1 × 107 MDA-MB-231 cells subcutaneous | Day 0 | 5 mg of iron injected with cells |
| 2 h × 21 days | Different timing | Tumor volume monitoring, HE label | |
| Li | C75BL/6 mice 1 × 105 MCF-7 cells subcutaneous |
| 2 mg of NP (in average) injected subcutaneously | 8 h after NP | 1 h | 24 h after MFE | HE label | |
| M. Chen | Athymic nude mice 5 × 106 U87 cells subcutaneous | Day 0, 2 and 4 | 5 mg kg−1 of NP injected intra-tumoraly | From day 1 | 30 min × 6 in 14 days | Day 21 | Tumor volume monitoring, apoptosis observation, HE label | |
| Athymic nude mice 2 × 106 U87 cells in orthotopic model (brain) | Day 0 | 2.5 mg kg−1 of NP injected intra-tumoraly | From day 2 | 20 min × 5 days | Along study | Survival study, HE label | ||
Fig. 5Extracted from Y. Cheng et al., 2015:[37]in vivo therapeutic efficacy of the magnetic particles (MPs) under rotating magnetic field. “The U87 cells were pre-incubated with MPs for 24 h and implanted in the mouse brain”. (a) Quantification of the tumor bioluminescence signal over 4 weeks (n = 5 mice per group). Data are presented as mean ± SE. **p < 0.01, ***p < 0.001 (Student's t test); (b) Kaplan–Meier survival curve of the mice with and without magnetic field treatment. *p < 0.05 (log rank test) [Reproducted with permission (ref. 37), Copyright© 2015, Elsevier B.V., J. Control. Release].